Technical Analysis for MRNS - Marinus Pharmaceuticals, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| See historical MRNS trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Feb 15 | Wide Bands | Range Expansion | 0.00% |
| Feb 14 | Crossed Above 50 DMA | Bullish | 4.95% |
| Feb 14 | 180 Bullish Setup | Bullish Swing Setup | 4.95% |
| Feb 13 | 50 DMA Resistance | Bearish | 11.05% |
| Feb 13 | Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 11.05% |
| Feb 13 | Outside Day | Range Expansion | 11.05% |
| Feb 12 | 50 DMA Resistance | Bearish | 8.52% |
| Feb 12 | NR7 | Range Contraction | 8.52% |
| Feb 12 | BB Squeeze Ended | Range Expansion | 8.52% |
| Feb 11 | 50 DMA Resistance | Bearish | 8.52% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2019-03-05
- Sector: Healthcare
- Industry: Pharmaceuticals
Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing neuropsychiatric therapeutics. It offers Ganaxolone, a synthetic small molecule, which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures; and is in proof-of-concept Phase II clinical trial as a treatment for behaviors in the orphan indication Fragile X Syndrome in children. The company has a collaboration agreement with NovaMedica, LLC, as well as a license agreement with Purdue Neuroscience Company. Marinus Pharmaceuticals, Inc. was founded in 2003 and is headquartered in New Haven, Connecticut.
Chemistry Physical Sciences Drugs Stage Biopharmaceutical Alcohols Ketones Pregnanes Sedatives Neurosteroids
Chemistry Physical Sciences Drugs Stage Biopharmaceutical Alcohols Ketones Pregnanes Sedatives Neurosteroids
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more MRNS news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 10.54 |
| 52 Week Low | 2.36 |
| Average Volume | 1,367,935 |
| 200-Day Moving Average | 5.6543 |
| 50-Day Moving Average | 3.4866 |
| 20-Day Moving Average | 3.4085 |
| 10-Day Moving Average | 3.599 |
| Average True Range | 0.2853 |
| ADX | 13.61 |
| +DI | 25.4043 |
| -DI | 20.3044 |
| Chandelier Exit (Long, 3 ATRs ) | 3.2041 |
| Chandelier Exit (Short, 3 ATRs ) | 3.8059 |
| Upper Bollinger Band | 3.9212 |
| Lower Bollinger Band | 2.8958 |
| Percent B (%b) | 0.9 |
| BandWidth | 30.083614 |
| MACD Line | 0.0529 |
| MACD Signal Line | 0.0067 |
| MACD Histogram | 0.0461 |
| Fundamentals | Value |
|---|---|
| Market Cap | 99.61 Million |
| Num Shares | 26.1 Million |
| EPS | -1.10 |
| Price-to-Earnings (P/E) Ratio | -3.47 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 7.28 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.18 | ||||
| Resistance 3 (R3) | 4.15 | 3.99 | 4.12 | ||
| Resistance 2 (R2) | 3.99 | 3.90 | 4.01 | 4.10 | |
| Resistance 1 (R1) | 3.91 | 3.85 | 3.95 | 3.94 | 4.08 |
| Pivot Point | 3.75 | 3.75 | 3.78 | 3.77 | 3.75 |
| Support 1 (S1) | 3.67 | 3.66 | 3.71 | 3.70 | 3.56 |
| Support 2 (S2) | 3.51 | 3.61 | 3.53 | 3.54 | |
| Support 3 (S3) | 3.43 | 3.51 | 3.52 | ||
| Support 4 (S4) | 3.46 |
